Larazotide half-life & pharmacokinetics

Reported half-life

Minimal systemic absorption is the design intent and a reported characteristic of larazotide acetate at therapeutic doses. Plasma concentrations in Phase II studies were very low or undetectable after oral 0.5 mg dosing, consistent with luminal site of action. Luminal transit half-life is governed by gastrointestinal transit time rather than systemic pharmacokinetics.

The half-life and pharmacokinetic profile of Larazotide reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Oral (capsule or tablet; luminal delivery; clinical use route)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Tight-junction modulator; zonulin pathway antagonist; synthetic octapeptide

Mechanism context

Half-life interpretation depends on the underlying mechanism. Larazotide acts as follows:

Larazotide acetate (AT-1001) is a synthetic octapeptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) originally derived from a structural sequence of the Vibrio cholerae surface protein zonula occludens toxin (Zot). Zot binds to host receptors in the intestinal epithelium, triggering a signalling cascade that results in redistribution of tight-junction proteins — occludin, claudin-1, claudin-3, and zonula occludens-1 (ZO-1) — away from the intercellular junction, thereby increasing paracellular permeability.

See the full Larazotide research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.